Smarter thinking about pharmaceutical marketingRobb DeFilippis, from end-to-end global creative production and sourcing partner Tag, discusses how a more effective multichannel pharma Share XSmarter thinking about pharmaceutical marketinghttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/tag-pharmaceutical-marketing-production/
Getting patients round the virtual tableIf pharma wants to be truly patient-centric, it needs to be talking to patients. This may seem obvious, Share XGetting patients round the virtual tablehttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/impetus-digital-patient-centric-engagement/
Revealing the true value of new cancer drugs to payersMarc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new Share XRevealing the true value of new cancer drugs to payershttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/pharmerit-cancer-drug-value-payers/
Adapting for the future of oncology trialsAdvanced analytical solutions provider Cytel is at the forefront of rapid changes in oncology R&D. We spoke with Share XAdapting for the future of oncology trialshttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/cytel-future-adaptive-trials-cancer/
Moving from autologous to allogeneic ACT paradigmsWe have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). The two marketed Share XMoving from autologous to allogeneic ACT paradigmshttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/icon-allogeneic-adoptive-cellular-transfer/
Did cancer clinical trials stay on track at ASCO 2019?Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference. Share XDid cancer clinical trials stay on track at ASCO 2019?https://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/kantar-cancer-clinical-trials/
Why pharma needs honest patient dialogueAstellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the Share XWhy pharma needs honest patient dialoguehttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/astellas-pharma-percival-barretto-ko/
Deep Dive: Oncology and ASCO 2019Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this Share XDeep Dive: Oncology and ASCO 2019https://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019
Time to fix pharma’s outdated business modelThe disconnect between payers and pharma companies is just one symptom of pharma’s outdated business model, according to Share XTime to fix pharma’s outdated business modelhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/janssen-kris-sterkens-pharma-business-model/
